Advaxis (NasdaqCM: ADXS) is a clinical stage biotechnology company developing immunotherapies to treat several types of cancer. The Company’s approach uses a Listeria-based delivery system to stimulate an immune response to specific cancer antigens. The Company’s initial focus is on cancers caused by human papillomavirus (HPV) infection, but the approach can be expanded to other indications. Advaxis has completed a Phase II trial in cervical cancer and has multiple trials ongoing in cervical, head and neck, anal, and prostate cancer. Three of these trials are in combination with other immune modulators through clinical collaborations with Merck, MedImmune, and Incyte.